Mira Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 248 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Media Coverage